Dr. Wick has been a Director of the Company since September 1998 and was our President from September 2002 to January 2006. Dr. Wick holds a doctorate degree in synthetic organic chemistry from the Swiss Federal Institute of Technology and has completed post-doctoral studies at Harvard University. He has had leading positions in the pharmaceutical research departments of F. Hoffmann-La Roche in the United States and Switzerland and Synthelabo in France (Director of Chemical Research and Development) for over 25 years in the field of antibiotics prostaglandin vitamins cardiovascular CNS and AIDS. Prior to joining Dragon Dr. Wick founded a fine chemicals company called Sylachim S.A. a 100% subsidiary of Synthelabo active in chemical intermediates and API’s and was its President until its acquisition by the German conglomerate mg Technologies (Dynamit-Nobel GmbH) in 2001. Dr. Wick is also a board member of STC a joint venture between Synthelabs (now Sanofi-Avantis) Tanabe of Japan and Herbonis a Swiss start-up company involved in extraction of medicinally useful components from plants.